Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis.
Acthar® Gel
Corticosteroid burden
Repository corticotropin injection
Sarcoidosis
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
02
06
2023
accepted:
27
07
2023
medline:
27
11
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
ppublish
Résumé
Long-term corticosteroid use in immune-mediated diseases is associated with increased risk of adverse events (AEs) and worsened health-related quality of life (HRQoL). Previous studies report chronic high-dose corticosteroid therapy results in higher rates of healthcare resource use and AE-related medical costs. Recent studies suggest Acthar A retrospective analysis of a large administrative pharmacy and medical claims database (Symphony Health Solutions) was conducted. Patients were included with confirmed ICD-9/10 diagnosis for sarcoidosis in the study period (2014-2020), followed by ≥ 2 Acthar Gel claims or comparators (janus kinase inhibitor (JAKi)/rituximab), ≥ 18 years old, with 12 months coverage pre/post index. Outcomes were compared as change from baseline. Acthar Gel adherence was determined by proportion of days covered in the follow-up period. The Acthar Gel (n = 735) and comparator (n = 626) cohorts were mostly female (68-72%) between 55 and 58 years old. Compared to the comparator cohort at baseline, Acthar Gel patients had greater any corticosteroid use (80% vs. 56%, p < 0.001), extended use (61% vs. 32%, p < 0.001), and mean average daily dose (6.72 vs. 3.03, p < 0.001). After treatment, Acthar Gel patients had greater reduction from baseline in any corticosteroid use (- 9.0% vs. - 3.2%) and extended use (- 10.0% vs. - 3.0%). In the Acthar Gel adherence cohorts, patients with above average adherence had greater reduction in both measures (- 11.2% vs. - 6.1%; - 11.6% vs. - 7.6%, respectively) than patients with below average adherence. Acthar Gel patients had greater reduction of extended use at all dose levels. Acthar Gel is associated with reductions in corticosteroid use compared to alternatives. Better adherence is associated with greater reduction in corticosteroid exposure. Key Summary Points. Patients who use corticosteroids long term for advanced sarcoidosis often suffer from negative health effects. This project aimed to evaluate whether Acthar
Autres résumés
Type: plain-language-summary
(eng)
Patients who use corticosteroids long term for advanced sarcoidosis often suffer from negative health effects. This project aimed to evaluate whether Acthar
Identifiants
pubmed: 37728695
doi: 10.1007/s12325-023-02630-x
pii: 10.1007/s12325-023-02630-x
pmc: PMC10567815
doi:
Substances chimiques
Adrenocorticotropic Hormone
9002-60-2
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4999-5015Informations de copyright
© 2023. The Author(s).
Références
Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.
Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet. 2014;383:1155–67.
doi: 10.1016/S0140-6736(13)60680-7
pubmed: 24090799
Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and management of sarcoidosis. Am Fam Physician. 2016;93:840–8.
pubmed: 27175719
Wu JJ, Schiff KR. Sarcoidosis. Am Fam Physician. 2004;70:312–22.
pubmed: 15291090
Jain R, Yadav D, Puranik N, Guleria R, Jin JO. Sarcoidosis: causes, diagnosis, clinical features, and treatments. J Clin Med. 2020;9(4):1081.
doi: 10.3390/jcm9041081
pubmed: 32290254
pmcid: 7230978
Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc. 2016;13:1244–52.
doi: 10.1513/AnnalsATS.201511-760OC
pubmed: 27509154
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.
doi: 10.1056/NEJMra071714
pubmed: 18032765
Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med. 2017;132:9–14.
doi: 10.1016/j.rmed.2017.09.003
pubmed: 29229111
Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58:2004079.
doi: 10.1183/13993003.04079-2020
pubmed: 34140301
Acthar Gel (repository corticotropin injection) [prescribing information]. Bridgewater, NJ: Mallinckrodt ARD LLC.
Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29:190146.
doi: 10.1183/16000617.0146-2019
pubmed: 32198218
pmcid: 9488897
Ross AP, Ben-Zacharia A, Harris C, et al. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol. 2013;4:21.
doi: 10.3389/fneur.2013.00021
pubmed: 23482896
pmcid: 3591751
Baughman RP, Barney JB, O’Hare L, Lower EE. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016;110:66–72.
doi: 10.1016/j.rmed.2015.11.007
pubmed: 26626451
Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195(3):313–22.
doi: 10.1007/s00408-017-9994-4
pubmed: 28353116
pmcid: 5437201
Chopra I, Qin Y, Kranyak J, et al. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records. Therap Adv Respir Dis. 2019;13:175346661988812.
doi: 10.1177/1753466619888127
Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. 2022 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–94.
doi: 10.1097/00004836-200110000-00006
pubmed: 11588541
Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204 (Crossref. PubMed).
doi: 10.2147/JAA.S176026
pubmed: 30214247
pmcid: 6121746
Rice JB, White AG, Johnson M, et al. Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. Curr Med Res Opin. 2018;34:1519–27 (Crossref. PubMed).
doi: 10.1080/03007995.2018.1474090
pubmed: 29741130
Rice JB, White AG, Johnson M, et al. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. J Med Econ. 2018;21:846–52 (Crossref. PubMed).
doi: 10.1080/13696998.2018.1474750
pubmed: 29741439
Moller DR. Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Eur Respir J. 2014;44(5):1123–6. https://doi.org/10.1183/09031936.00156314 .
doi: 10.1183/09031936.00156314
pubmed: 25362122